Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection

Alfredo B. Cuéllar-Barboza, Susan L. McElroy, Marin Veldic, Balwinder Singh, Simon Kung, Francisco Romo-Nava, Nicolas A. Nunez, Alejandra Cabello-Arreola, Brandon J. Coombes, Miguel Prieto, Hannah K. Betcher, Katherine M. Moore, Stacey J. Winham, Joanna M. Biernacka, Mark A. Frye*

*Autor correspondiente de este trabajo

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

5 Citas (Scopus)

Resumen

Background
Treatment in bipolar disorder (BD) is commonly applied as a multimodal therapy based on decision algorithms that lack an integrative understanding of molecular mechanisms or a biomarker associated clinical outcome measure. Pharmacogenetics/genomics study the individual genetic variation associated with drug response. This selective review of pharmacogenomics and pharmacogenomic testing (PGT) in BD will focus on candidate genes and genome wide association studies of pharmacokinetic drug metabolism and pharmacodynamic drug response/adverse event, and the potential role of decision support tools that incorporate multiple genotype/phenotype drug recommendations.

Main body
We searched PubMed from January 2013 to May 2019, to identify studies reporting on BD and pharmacogenetics, pharmacogenomics and PGT. Studies were selected considering their contribution to the field. We summarize our findings in: targeted candidate genes of pharmacokinetic and pharmacodynamic pathways, genome-wide association studies and, PGT platforms, related to BD treatment. This field has grown from studies of metabolizing enzymes (i.e., pharmacokinetics) and drug transporters (i.e., pharmacodynamics), to untargeted investigations across the entire genome with the potential to merge genomic data with additional biological information.

Conclusions
The complexity of BD genetics and, the heterogeneity in BD drug-related phenotypes, are important considerations for the design and interpretation of BD PGT. The clinical applicability of PGT in psychiatry is in its infancy and is far from reaching the robust impact it has in other medical disciplines. Nonetheless, promising findings are discovered with increasing frequency with remarkable relevance in neuroscience, pharmacology and biology.
Idioma originalInglés
Número de artículo23
PublicaciónInternational Journal of Bipolar Disorders
Volumen8
N.º1
DOI
EstadoPublicada - 1 dic. 2020

Nota bibliográfica

Publisher Copyright:
© 2020, The Author(s).

Huella

Profundice en los temas de investigación de 'Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection'. En conjunto forman una huella única.

Citar esto